Skip to Content

Join the 'Lucentis' group to help and get support from people like you.

Lucentis News

FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy

Posted 28 Mar 2018 by Drugs.com

South San Francisco, CA – March 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. In April 2017, Lucentis 0.3 mg became, and remains, ...

FDA Approves Genentech’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy

Posted 19 Apr 2017 by Drugs.com

South San Francisco, CA – April 17, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of ...

FDA Approves Genentech’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization

Posted 10 Feb 2017 by Drugs.com

South San Francisco, CA – January 5, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularization (mCNV), a complication of severe near-sightedness that can lead to blindness. Lucentis is the ...

FDA Approves Genentech’s Lucentis (ranibizumab) Prefilled Syringe

Posted 17 Oct 2016 by Drugs.com

South San Francisco, CA – October 14, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related ...

Newer Drugs Helping Older People With Eye Disease

Posted 21 May 2016 by Drugs.com

FRIDAY, May 20, 2016 – New medications are boosting quality of life for many older people with age-related macular degeneration (AMD), a new study indicates. The drugs Avastin and Lucentis have significantly increased the number of people with AMD whose vision remains good enough to do daily activities, such as read standard print or drive, researchers found. Age-related macular degeneration is ...

Study Compares Drugs for Common Diabetic Eye Disease

Posted 29 Feb 2016 by Drugs.com

MONDAY, Feb. 29, 2016 – People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease – Avastin, Eylea and Lucentis – vary widely in price, but new research suggests all work equally well for patients with mild vision loss. However, when diabetic macular edema leads to more severe vision loss, researchers found ...

Drug Lucentis May Fight Diabetic Eye Disease

Posted 13 Nov 2015 by Drugs.com

FRIDAY, Nov. 13, 2015 – The injected drug Lucentis (ranibizumab) appears highly effective at treating proliferative diabetic retinopathy, a common diabetes-related eye disease, new research shows. Investigators say the drug beat a standard treatment, laser therapy, in curbing the vision-robbing ailment. The findings, "provide crucial evidence for a safe and effective alternative to laser therapy ...

Drug Avastin Not Linked to Higher Risk of Blindness: Study

Posted 13 Aug 2015 by Drugs.com

THURSDAY, Aug. 13, 2015 – Concerns that eye injections of the drug Avastin increase the risk of a potentially blinding eye infection may be unfounded, a new study finds. Researchers analyzed insurance claims data from across the United States to compare the use of Avastin (bevacizumab) to treat retinal diseases with a much more expensive drug called Lucentis (ranibizumab). The study was ...

Study Compares Drugs for Diabetes-Linked Eye Disease

Posted 18 Feb 2015 by Drugs.com

WEDNESDAY, Feb. 18, 2015 – A vision-robbing condition called diabetic macular edema can strike people with diabetes. Now, a new study compared three leading drugs for the condition – Avastin, Eylea and Lucentis – and found that Eylea came out on top, at least for patients with "moderate" vision loss. The study, funded by the U.S. National Eye Institute (NEI), "will have a dramatic impact on ...

Lucentis Approved for Diabetic Retinopathy

Posted 9 Feb 2015 by Drugs.com

MONDAY, Feb. 9, 2015 – A drug to treat the most common eye disease among diabetics has been approved by the U.S. Food and Drug Administration. Lucentis (ranibizumab) has been sanctioned to treat diabetic retinopathy, the leading cause of blindness among adults in the United States, the FDA said in a news release. In 2008, one-third of diabetic adults 40 or older had some form of diabetic ...

FDA Approves Lucentis as First Drug for Diabetic Retinopathy

Posted 8 Feb 2015 by Drugs.com

FRIDAY, Feb. 6, 2015 – The U.S. Food and Drug Administration on Friday approved the drug Lucentis (ranibizumab) to treat diabetic retinopathy in patients with diabetic macular edema. A leading cause of blindness among adults in the United States, diabetic retinopathy is the most common diabetic eye disease, the agency said in a news release. In 2008, 33 percent of adults with diabetes aged 40 or ...

FDA Approves Lucentis (ranibizumab) to Treat Diabetic Retinopathy in People with Diabetic Macular Edema

Posted 6 Feb 2015 by Drugs.com

February 6, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). Diabetic retinopathy is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and ...

FDA Approves Lucentis (ranibizumab) for Treatment of Diabetic Macular Edema (DME)

Posted 13 Aug 2012 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 10, 2012 - Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness. Diabetes is now the ...

Lucentis Approved for Diabetic Macular Edema

Posted 10 Aug 2012 by Drugs.com

FRIDAY, Aug. 10 – Lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration to treat diabetic macular edema (DME), an eye condition that could threaten a diabetic person's sight, the agency said Friday in a news release. The condition occurs when fluid leaks into the macula, the center of the eye's retina. This leads to macular swelling, causing blurred vision. ...

Eye Antibiotics Can Cause Drug-Resistant Bacteria: Study

Posted 12 Sep 2011 by Drugs.com

MONDAY, Sept. 12 – Repeated use of antibiotics among patients who receive eye injections for such ophthalmic conditions as age-related macular degeneration can lead to the emergence of drug-resistant germs, according to a new study. More than eight million people in the United States are affected by age-related macular degeneration, and its treatment involves monthly injections that are ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema, Myopic Choroidal Neovascularization

Lucentis Patient Information at Drugs.com